19 20 21 31 delivery device design. We describe how the miniaturisation of these devices 32 enables the move from repeated, systemic dosing, to on demand, targeted 33 delivery of therapeutic drugs, and highlight areas of focus for the future.
Drug delivery across length scales 22
Over the last century there has been a dramatic change in the nature of 23 therapeutic, biologically active molecules available to treat disease. Therapies 24 have evolved from extracted natural products towards rationally designed 25 biomolecules, including small molecules, engineered proteins, and nucleic acids.
26
The use of potent drugs which target specific organs, cells, or biochemical 27 pathways, necessitates new tools which can enable controlled delivery and dosing 28 of these therapeutics to their biological targets. Here, we review the 29 miniaturisation of drug delivery systems from the macro-to nano-scale, focusing 30 on controlled dosing and controlled targeting as two key parameters in drug
INTRODUCTION 38
Over the last century there has been a dramatic change in the nature of therapeutic, 39 biologically active molecules available to treat disease. This is represented by the move 40 from extracted natural products and synthesised natural product mimics 1 , towards 41 rationally designed biomolecules including small molecules, engineered proteins, and 42 nucleic acids [2] [3] [4] . The evolution of potent drugs which target specific organs, cells, or 43 biochemical pathways, necessitates new tools which can enable controlled delivery and 44 dosing of these therapeutics to their biological targets. Therapies which can be 45 administered as a single procedure, either through the delivery of a single dose of a 46 potent curative therapeutic, or through the implantation of a device that can maintain a 47 precise, long term drug dosing regime, are highly desired. 48
Macro-scale drug delivery devices have been widely adopted since the 1970s, 49 when long-acting intra-uterine contraceptive implants were offered as an alternative to 50 daily repeated oral administration of systemically released hormones 5 . These implants 51 could be inserted during a single procedure, and remained effective for several years 52 through localised and controlled release of contraceptive hormones. Since then, a wide 53 range of systems for therapeutic drug delivery have been developed, broadly focused on 54 systems which can help to regulate drug dosing 6 , and those which aid targeted delivery 55 for site-specific therapeutic action 7-10 . Drug delivery devices are in widespread clinical 56 use, however, many of these systems are limited in their ability to deliver therapeutics 57 to smaller biological structures with control over both drug dosing and therapeutic 58 targeting. 59
For certain drugs, failure to adhere to a specific dosing schedule can 60 dramatically impact therapeutic efficacy. In vaccination, the timing of drug dosing (e.g. be administered without surgical intervention. Although ingestible devices offer a robust 110 controlled delivery system that can passage through the gastro intestinal (GI) system, 111 orally delivered drugs must first be absorbed through the gut to become bioavailable. The 112 GI tract consists of the stomach, small intestine (duodenum, jejunum and ileum), the large 113 intestine (colon), and the rectum; drug absorption can occur across the entire GI tract. The 114 majority of drug absorption is occurs via the highly adapted microvilli in the small 115 intestine, however class III/IV drugs have been shown to preferentially absorb across the 116 colon 36 . Several drug delivery systems utilise the distinct chemical environments present 117 in specific regions of the gastrointestinal tract to facilitate a more targeted drug delivery 118 approach, discussed in detail in the targeted delivery section below. Regardless of 119 absorption site, orally administered drugs are subject to first-pass metabolism and hepatic 120 clearance, and so systemic bioavailability of a therapeutic drug concentration may be 121 lower when compared to intravenous administration. 122
Transdermal delivery 123
In contrast to ingestible devices, transdermal drug delivery methods offer many benefits 124 over the more traditionally administered oral route 37 . Firstly, compared to orally 125 delivered pharmacologics of the same dose, they can provide increased levels of 126 circulating, bioavailable drugs. This leads to a reduction in the drug dose needed to 127 elicit a specific pharmacological effect [38] [39] [40] , and can therefore reduce side effects. 128
Transdermal patches provide a controlled release system which is well suited to the 129 delivery of small molecules, though dermal penetration and delivery efficacy is affected 130 by both the molecular size and hydrophilicity of the therapeutic being administered. 131 systemic delivery of low dose therapeutics. Drug delivery profiles range from a few 135 days to a few weeks due to limitations in drug loading capacity, and patches must 136 remain attached to the skin for the duration of delivery. 137 have been used to systemically deliver a range of pharmaceuticals including anti-145 inflammatory drugs and antibiotics [45] [46] [47] [48] . As with the early Norplant® devices, many of 146 these systems are based on non-degradable polymers with a fixed-rate delivery profile, 147 controlled by drug diffusion from within the device. Devices are usually implanted, and 148 removed, via a minor surgical procedure at the end of their delivery lifetimes. To 149 minimise surgical intervention required in the removal of these devices, longer-acting, 150 degradable subcutaneous rod implants are currently in development 49 . 151
Polymer implants
In a similar approach, polymer hydrogel systems can be used for kinetically 152 controlled systemic drug release 7, 13, 50 . Hydrogels have the potential to deliver virtually 153 any therapeutic 13, 51 ; controlled release parameters are widely tuneable, with the nature 154 of the hydrogel crosslinking determining the kinetics of controlled release and the 155 biodegradability of the system. Both chemical (covalent) and physical (electrostatic 156 assembly, stereo-complexation, supramolecular host-guest inclusion) crosslinking can chemistries and polymer compositions provides tuneable delivery profiles that can last 160 from several days up to several years, making polymer implants a versatile class of 161 materials for drug delivery. 162
Pump systems 163
A number of implantable infusion pump systems have been developed for long-term 164 delivery of therapeutics with metered dosing 23 . These devices can measure up to 10 cm 165 in diameter, and are often surgically implanted into patients. They generally consist of a 166 reservoir-pump system which offers dosing schedules based on continuous fixed rate 167 delivery, timed dose delivery, or on-demand delivery in response to specific stimuli. 168 Dosing is usually controlled by an integrated pump system, which can be driven 169 through mechanical, peristaltic means 52-55 , propellant systems 56-59 , or is driven by 170 osmosis/diffusion 60 . Due to the invasive surgical nature of implantation, these devices 171 are primarily used for continuous therapeutic release in chronic medical conditions 54, 56, 172 57 . Examples include intrathecal delivery of opioid based analgesic therapies, or delivery 173 of muscle relaxants such as baclofen in patients with severe contractions. This 174 continuous, metered dosing is particularly useful for analgesics in long term and 175 palliative care, where the risk of misadministration and accidental overdose, a current 176 concern with prescribed opioid tablets, can be reduced. 177
For metered and on-demand dosing, stimuli responsive pumps can be used. 178
These have proven particularly useful in diabetes, where sensors implanted under the 179 skin can monitor and respond to glucose levels (MiniMed, Paradigm® Revel™) 61 . In 180 these systems, reservoirs containing insulin, or twin reservoirs containing insulin and 181 glucagon, are connected to sensors and facilitate metered drug delivery in response to 182 hypo-or hyper-glycaemic events. Recently, wireless, smartphone connected sensors 183 have been developed which allow patients and healthcare professionals to manage 184 glucose levels in real time 62, 63 . These devices enable a truly patient specific, on-demand 185 therapy, and are now clinically used in systemic applications 60, 62, 64 . However, the 186 reservoir-based systems described limits the drug formulations to liquid systems, and 187 device lifetimes are limited by the reservoir loading capacity. Additionally, the use of a 188 power source to run the pumps in peristaltic devices limits the usefulness of these 189 devices due to short battery lifetimes (usually limited to 4-7 years) 65 . Finally, due to 190 their scale these more complex systems currently remain unsuitable for targeted or 191 localised delivery approaches, which require smaller scale devices. 192
Localised delivery systems 193

Proximal polymer implants 194
Many smaller macro scale devices can be surgically implanted within target organs to 195 allow for proximal drug release, enabling therapeutic efficacy using lower doses than 196 required in systemic delivery systems. A widespread example are contraceptive devices 197 introduced into the body via the vaginal tract. Contraceptive devices, briefly discussed 198 earlier, are widely adopted clinically, and intra uterine devices (IUDs) 5 To reach less accessible target organs, surgical intervention is often required to 208 position macro devices correctly. A number of polymer-based macro devices are 209 indicated for controlled drug delivery to target organs, exemplified by stent-based 69 210 drug delivery. Stents are used for drug delivery in coronary interventions, and 211 additionally in non-vascular target organs including the oesophagus, biliary duct, 212 trachea, bronchi, sinus cavities, ureters, and urethra 70, 71 . First-generation vascular stents 213 were approved by the FDA in 1994, and were manufactured from bare metal alloys or 214 ceramic composites. However, these stents caused complications including hyperplastic 215 growth and restenosis. Next generation stents therefore included novel metallic and 216 polymeric stent materials with more open mesh-like frameworks, and simultaneously 217 eluted anti-inflammatory drugs 71, 72 to reduce restenosis. Stents often provide a physical 218 support coupled with drug eluting capabilities. The continued optimisation of stent 219 structures to reduce plaque prolapse (through increased radial strength) and increase 220 biocompatibility (using fluoropolymer materials) renders these devices as versatile tools 221 for the delivery of a diverse class of drugs. Many systems have been developed for the 222 controlled delivery of anti-inflammatory, antimicrobial, and analgesic drugs 70, 71 using 223 diffusion based release profiles. 224
In contrast, less rigid polymer systems, have been used for non-structural drug 225 delivery. Both biodegradable polymer stents, and implantable hydrogel systems can be 226 used for localised therapeutic delivery. Biodegradable polymer systems are particularly 227 useful for non-structural drug delivery systems 70 , as they can be packed into surgical 228 sites and release drugs during healing before being resorbed into the body. These 229 polymer systems have been used in applications ranging from advanced wound healing 230 to the delivery of chemotherapeutics 73, 74 . In contrast, macro scale polymer-based 231 hydrogel systems are useful for both surgical and non-surgical drug administration. A 232 widespread example is hydrogel contact lenses used for ocular drug delivery. These 233 devices can increase the bioavailability of drugs otherwise limited by burdensome 234 ocular administration dosing regimens 48, 75 . They have proven particularly useful for 235 delivery of medications for eye diseases including glaucoma, and delivery of 236 antibacterial agents to the eye 76-78 . In general, hydrogel thickness can be used to control 237 drug loading, and delivery profiles can be tuned to offer zero-order release kinetics. 238
Many hydrogel systems are unsuitable for localised ocular delivery applications due to 239 their limited transparency, stability, and the use of non-biocompatible crosslinking 240 agents during formation. Drug delivery contact lenses must be designed to possess 241 luminous transmittance, oxygen permeability, mechanical stability, and 242 biocompatibility 76-79 in addition to their drug loading capacity. These stringent material 243 requirements highlight the complexities in designing drug delivery systems which 244 match localised tissue requirements. Next, we discuss advances in macro scale drug 245 delivery systems which enable a more targeted delivery approach. 246
Targeted delivery systems 247
Targeted delivery systems, where a device enables the delivery of a therapeutic to a 248 target organ or cell based in a different location to the administration site, are relatively 249 limited in macro scale devices. Due to their scale, macro devices are often too large to 250 engage with many biological structures and target cells. A notable exception to this is 251 the use of stimuli responsive macro scale devices for delivery to chemically distinct 252 regions of the gastrointestinal tract 34, 80-82 . The chemical environment of the stomach 253 often poses a challenge to pH sensitive and enzymatically degraded protein and peptide 254 therapeutics. Drug delivery devices frequently utilise local variations in target tissue pH 255 to control drug release, with hydrogels sensitive to alkali pH and enteric tablet coatings 256 facilitating delivery to the intestines. For many other target tissues, macro scale devices are too large to travel through the 258 vasculature or lymphatic system and move towards target organs. In an alternative 259 approach, macro devices which can recruit a target cell towards the device to selectively 260 deliver a therapeutic drug to a target cell type have been developed. These devices have 261 been trialled in vaccination systems, where chemokines (CXCL12) have been 262 incorporated into a polymer material to encourage the recruitment of immune cells. 263
Once the immune cells reach the macro device, they "collect" the drug. In this way, the 264 macro device can overcome the transport limitation imposed due to its size, and 265 provides a targeted delivery system to specific cells by recruiting the cell of interest 83-85 266 to the device location. This relatively new concept offers promise for the design of a 267 range of macro devices which can act in a targeted manner 268
Summary 269
Macro scale devices and their component parts can be precisely engineered to allow fine 270 control over drug dosing schedules, and in some cases, can be coupled with sensor 271 technology to enable patient specific systemic drug release. The dimensions of most 272 macro scale devices and their capacity to hold large therapeutic reservoirs renders them 273 suitable to long term drug delivery. However, these dimensions also limit their 274 usefulness in targeting smaller biological structures. Although some smaller macro 275 devices can be surgically inserted into larger target organs (i.e. uterus, large arteries) to 276 facilitate proximal or localised drug release, devices cannot migrate through the body, 277 limiting their ability to deliver drugs in a targeted fashion. The advent of new polymer 278 implants which can directly recruit target cells offers the potential to combine the 279 intrinsic advantages of macro devices (drug loading capacity, precision engineering, 280 patient specific stimuli responsive systems) with the targeting advantages usually found 281 in smaller scale systems, and is an exciting future direction for macroscale device 282 development. 283
MICRO SCALE DELIVERY SYSTEMS 284
Devices at the micron scale range from 1-1000µm, allowing them to be introduced 285 within the body without the need for a major surgical procedure through ingestion 286 (orally administered osmotic pumps) 24, 86, 87 , inhalation, and inoculation (microparticles, 287 microneedles) 88-92 . Many key biological structures are organised on the micron length 288 scale, with cells themselves measuring from 5-20 microns in diameter and possessing 289 cellular substructures on the order of nano-to micro-meters. Several biological transport 290 networks are also organised on the micro-scale; lymphatic capillaries 93, 94 have a 291 diameter of ~10-60 µm, whilst circulatory vasculature 95 measures on the order of 10 292 mm in arteries and veins to around 1 µm in capillaries. Micro-scale drug delivery 293 devices therefore offer the unique advantage of being able to interface with organoid, 294 cellular, and subcellular structures on a comparable length scale to their biological 295 targets. In addition, they may be able to navigate through the body's transport networks, 296 rendering them particularly suitable for localised and targeted delivery systems. Here, 297
we review a range of micro scale delivery systems with increasing target specificity. 298 implantation. Due to the placement of these devices within the body, refilling these 320 systems will likely require an additional surgical procedure, rendering these devices 321 unsuitable for non-surgical applications. 322
Systemic delivery systems 299
Microneedles 323
Microneedle patches have been developed which facilitate drug delivery without 324 surgical intervention. These consist of an array of high aspect ratio needles 90, 91 on the 325 order of 500-1000 µm in length, which can penetrate the epidermis and reach the 326 underlying dermal layer. Once they are in contact with this layer, they can be used to 327 deliver small molecules, proteins, or nucleic acids via hollow, solid, or biodegradable 328 needles 30 . The needles are usually made of metal, silica, or polymer composites, and are 329 fabricated through microlithography 29, 88-91, 111 using etching, casting, or printing 330 methods. The simplest of these systems use solid and porous non-degradable needles 331 coated with a drug, or biodegradable drug-polymer composite that can dissolve into the 332 tissue once the microneedles contact the dermal layer. Alternatively, the microneedles 333 can be uncoated, and removed once they have penetrated the epidermal barrier, 334 allowing topical application of therapeutics to the area. An alternative system uses 335 hollow needles coupled to a liquid reservoir, using capillary action to inject liquid into 336 the dermal layer in an analogous manner to traditional macro needles. In contrast, 337 biodegradable needle systems can be applied directly to the skin and used to deliver 338 drugs with a more continuous release profile. By carefully tuning polymer 339 compositions, these systems can controllably deliver drugs in a single administration 340 lasting a few seconds, or with a longer kinetic release profile of a few weeks 30, 90 . 341 overloading the subcutaneous space with polymer materials, hydrogels with tuneable 357 degradation rates (matched to the rate of drug release) can ensure polymer residue does 358 not remain in the body after the therapeutic has been delivered. As an alternative, 359 refillable drug delivery depots have recently been developed, which aim to overcome 360 the drug loading limitations inherent in microscopic drug delivery depots. These 361 systems use "tagged" drugs which can be administered intravenously and migrate 362 towards the polymer depot 118, 119 , providing a refillable controlled release depot. 363
Microparticles 364
Microparticles typically consist of a degradable, drug loaded microparticle that acts as a 365 drug delivery depot. These particles can be suspended in saline, and injected 366 intravenously where, if appropriately sized, they circulate systemically. Microparticles 367 are typically formed by emulsion or solvent evaporation techniques 15, 32, 120-125 , 368 potentially resulting in a loss of potency for sensitive therapeutics after exposure to 369 organic solvents during the fabrication method. In an alternative approach, ultra-370 sonication and freezing can be used to generate microparticles with control over 371 polydispersity [11] , reducing the need for organic solvents and maintaining drug 372 potency. A variety of polymers have been used to fabricate microparticles, and the 373 choice of polymer directly impacts both the microparticle targeting ability and the 374 specific release kinetics. For example, PLGA microparticles are FDA approved for 375 clinical use in a range of applications, including chemotherapeutic drug delivery and 376 hormone release. Their release profiles can be tuned to continuously deliver therapeutic 377 load over the course of two days, or for up to eight weeks, depending on the lactide to glycolide ratio 126-128 within the polymer. Recently, more advanced microparticles have 379 been developed which offer a more complex kinetic release profile. These materials 380 combine several different polymer architectures to offer a single particle that can release 381 therapeutic load in 2-3 distinct bursts. These systems are likely to prove extremely 382 useful in vaccine development, where an entire multi-dose vaccination schedule could 383 be administered systemically in one injection 11, 129 . 384
Localised delivery systems 385
Implantable microchips 386
As infusion pump and microchip devices have been miniaturised, they have become 387 increasingly suitable for localised drug delivery applications. Recently, new MEMS 388 devices have been developed which offer an implantable "pharmacy-on-a-chip" design, 389 allowing the delivery of multiple therapeutics, each at a specified time. These devices 390 can provide precise dosing control through as many as 100 unique reservoirs opened on 391 the order of microseconds. The first "pharmacy-on-a-chip" devices successfully 392 completed phase one human clinical trials in 2012, and were used to deliver human 393 parathyroid hormone fragment 86, 130 to eight osteoporotic patients. Taking this 394 technology further, micron-sized reservoir-based devices holding up to 100 drugs and 395 drug combinations in a small microchip have been implanted into tumour sites. Due to 396 their high aspect ratio and small scale, implants can be extracted using a conventional 397 biopsy needle, and the tissue can be examined to determine tumour regression in 398 response to each of the therapeutic drugs and drug combinations tested. In this way, 399 surgeons and oncologists can develop a personalised drug treatment plan for cancer 400 patients based on positive responses to specific drug combination therapies 131, 132 , tested 401 using the microchip. 402
Controlled polymer architecture 403
Polymers can be modified to display controlled topographical and physical features, 404 enabling delivery of therapeutics to a specific biological target organ. For example, the 405 Nektar aerosolised inhaler based systems deliver microparticles containing a range of 406 therapeutics, and uses microparticles with a reduced density to aid pulmonary particle 407 delivery 133 . Microparticle geometry has also been shown to directly impact cellular 408 uptake, with both particle size and shape 134-138 playing an important role in the response 409 of specific tissues and cells. Given the importance of the three dimensional structure to 410 cellular interactions, shape memory polymers are being developed that can be injected 411 into a target organ using a syringe, and then resume a specific 2D or 3D shape on 412 reaching 37°C in the body. One example of these systems involves bio-adhesive shape 413 memory hydrogel sheets, which provide an easily applied, injectable patch drug 414 delivery device for local drug administration 72, [139] [140] [141] [142] . 415
Targeted delivery systems 416
Ligand targeting 417
The identification of organ and cell specific ligands has facilitated targeted delivery of 418 micro scale systems. This is often accomplished using conjugation strategies which link 419 targeting ligands onto polymers. Ligand conjugated polymers can be used to form drug 420 delivery microparticles, which can be formulated to encapsulate a range of therapeutic 421 cargo including proteins, small molecules, and cytokines within a ligand decorated 422 polymer shell 17, 143 . Conjugation of specific ligands can also alter the systemic 423 circulation time; for example the inclusion of a polyethylene glycol (PEG) moiety is 424 thought to prevent binding and uptake of microparticles by non-targeted cell types. The 425 inclusion of specific ligands facilitates microparticle binding to specific cells and tissues 426 presenting the receptor for the attached ligand. These systems have proven particularly 427 useful for targeting the liver though the ASGPR1 receptor 144, 145 , or targeting 428 systemically circulating dendritic cells 146, 147 . As ligands of other target organs are 429 identified, this method will enable more specific targeting. 430
Microbubbles 431
In an alternative approach, smaller, drug loaded microbubbles have been injected 432 systemically. The application of ultrasound (which bursts these bubbles) can be used to 433 target drug release to a specific therapeutic area. This emerging technology makes use 434 of clinically available imaging facilities located in hospitals and clinics to induce 435 controlled release in target biological structures. The technique has proven popular in 436 delivering drugs to larger target organs, such as the kidney [148] [149] [150] To improve solubility, drugs are often encapsulated inside micelle carriers, or 481 conjugated to water soluble polymers. Liposome-based carriers were first described in 482 the 1960s and are amongst the most well established nano-carriers for systemic delivery 483 157 . They have been widely used to improve aqueous solubility of hydrophobic drugs, 484 illustrated by the antifungal amphotericin B, which is insoluble at physiological pH and 485 also highly toxic. The liposomal formulation of this drug, AmBisome®, can be 486 administered systemically with dramatically reduced toxicity 158-160 . 487 Synthetic conjugates have also been used to formulate drug delivery nanoparticles, and 488 inclusion of water soluble polymers, such as polyethylene glycol, can aid systemic 489 solubility without the inclusion of dose-limiting solvents. Paclitaxel is an example of a 490 poorly water-soluble drug that has been formulated within degradable polylactide-491 polyethylene glycol block co-polymers, allowing better delivery through nanoscale drug 492 delivery micelles (Genexol-PM). These micellar nanoparticle formulations can also 493 enhance transdermal drug delivery [161] [162] [163] , and have been used to deliver hormones such 494 as estradiol via topical application.The incorporation of polyethylene glycol (PEG) into 495 these nanoparticle systems can increase particle stability [164] [165] [166] , reduce protein 496 adsorption (opsonization), and prevent subsequent phagocytic clearance. For example, 497
PEGylated liposomal doxorubicin formulations have been shown to extend circulation 498 times 164, 167 when compared to uncoated liposomes, or free doxorubicin. However, 499 studies have indicated that repeated administration of PEGylated formulations can lead 500 to an increased clearance rate of subsequent doses of PEGylated liposomes. This is 501 likely due to IgM antibodies raised after first exposure 164 or pre-existing IgG antibodies 502 to PEG. 168 503
Nanowires, nanoneedles and nanotubes 504
High-aspect-ratio nanoscale systems 169-171 such as nanowires, nanoneedles and 505 nanotubes have been used to deliver a wide variety of biomolecules, and can be 506 combined with macro and micro systems to enhance drug delivery technologies. For 507 example, micron scaled drug delivery particles have been coated with nanowires which 508 enhance retention in the mucosal tract. This strategy enables prolonged retention to 509 mucosal epithelial tissue 172 , facilitating enhanced drug delivery and limiting clearance. 510
In addition, nano scale needles (nanoneedles), wires, and tubes can be loaded directly 511 with drugs for intracellular drug delivery. Biodegradable silicon nanoneedles grafted 512 onto micron sized patches have been used for the intra-cellular delivery of VEGF DNA 513 to localised regions of skin and exposed muscle 169 , where they are able to enhance 514 neovascularization compared to delivery of naked DNA. Recently, more sophisticated 515 systems have been developed which can release cargo in response to specific stimuli 29, 516 92 , including changes in pH and temperature, and the presence of specific enzymes. 517
High-aspect delivery systems are typically silicon-based, however alternative materials 518 (such as carbon nanotube based drug reservoirs 173-176 ) are currently being developed. 519
These material systems will need to meet stringent nano scale safety and toxicity 520 requirements before widespread clinical use.
Nanogels 522
Nanoscale hydrogels (nanogels) broadly consist of crosslinked polymeric particles 523 which can be synthesized using a range of synthetic and naturally derived materials 524 including polyacrylamides, polydimethylsiloxane, and chitosan 166, [177] [178] [179] [180] . Nanogels offer 525 a large surface area for bioconjugation, and as for the microgel systems described 526 earlier, cross-linking can be used to fine tune drug delivery release kinetics for the 527 delivery of hydrophobic, hydrophilic and charged solutes. Nanogels have been used for 528 both targeted intracellular delivery and systemic delivery. These systems have recently 529 been applied to intra-nasal vaccine delivery, where they can be retained in nasal mucosa 530 to generate systemic immunity as well as local mucosal immunity 181, 182 . 531
Localised delivery systems 532
Stimuli responsive nanosystems 533
In an effort to move towards systems with spatio-temporal control of drug delivery, a 534 number of nanosystems have been developed which can be triggered to release cargo by 535 exposure to external stimuli such as heat, light and ultrasound. Ultrasound has been 536 utilized to increase transdermal delivery of a variety of nanoparticles through the skin 29, 537 149, 150 , whilst heat and light sensitive nanosystems have enabled delivery to deeper 538 tissues. For example, thermosensitive lipids that have transition temperatures between 539 40-45°C can be used to formulate liposomes that become unstable and release cargo 540 once exposed to this temperature. ThermoDox® is a temperature-sensitive doxorubicin-541 PEGylated liposome that is systemically delivered but releases cargo in regions where 542 local temperatures are elevated to 40 °C by application of radiofrequency. The thermo-543 responsive formulation was shown to increase local concentration of the drug several 544 folds higher in the radiofrequency treatment area compared to intravenously 545 administered doxorubicin, and compared to non-thermosensitive liposomal formulations 546 of doxorubicin 183 . 547
Alternatively, light has been used as an external stimulus for photodynamic 548 therapies. Visudyne® is a liposomal formulation of verteporfin 184, 185 used to treat 549 ocular conditions. It is systemically administered but only exerts its toxic effects when 550 exposed to light. When light is applied to the eye, this formulation can be used to treat 551 ocular neovascularization due to diseases such as age-related macular degeneration. For 552 these treatments to be successful, stimuli must be able to penetrate to the target tissue to 553 facilitate drug release. This renders tissues closer to the surface more amenable to these 554 therapies; for deeper structures alternative targeted delivery systems are required. 555
Targeted delivery systems 556
Site-specific accumulation 557
Systemically delivered nanoparticle systems may accumulate in organs such as the 558 liver, lung and in tumors. This site-specific accumulation after systemic administration 559 has been observed using nanocarriers where there is no specific targeting moiety. 560
Nanoparticles that tend to accumulate at tumor sites are thought to be subject to the 561 enhanced permeability and retention 186 (EPR) effect. Nanoparticles are small enough to 562 traverse through the leaky blood-tumor barrier resulting in accumulation and therefore 563 enhanced drug delivery to the tumor site. Lung accumulation is thought to be due to the 564 cationic nature of nanoparticles leading blood component aggregation and accumulation 565 in pulmonary vasculature. 187, 188 566 Selective biodistribution has also been attributed to in vivo post-modification of 567 nanoparticles, where particular apolipoproteins are preferentially adsorbed onto the 568 nanoparticle, and can facilitate trafficking to, and enhance retention in, the 569 corresponding organ. In one example, polysorbate 80 modified polybutylcyanoacrylate 570 nanoparticles were used to deliver doxorubicin to the brain. Doxorubicin does not cross 571 the blood brain barrier alone, but when delivered as a nanoparticle formulation, delivery 572 to the brain was achieved 189 and found to be due to adsorption of apolipoprotein onto 573 the polymer nanoparticles. Similarly, lipid nanoparticles carrying nucleic acids were 574
shown to accumulate in the liver after adsorption of apolipoprotein E 190, 191 . These 575 examples demonstrate that nanoparticle design must consider factors such as particle 576 size, charge and shape 170, 192 , which can influence tissue accumulation and therefore 577 targeting efficacy. 578
Receptor-mediated targeting 579
In a similar manner to microparticle based delivery, nanoparticles can be formulated 580 with protein and ligand tags to enable selective delivery. Identifying specific receptor 581 ligand pairs which enable cell selective delivery is a topic of great interest. To reduce 582 phagocytosis and enhance therapeutic efficacy, nanosystems can be conjugated with 583 "self" peptides such as CD47 193 which act as a "don't eat me" marker. For tumor 584 targeting, nanoparticles can be decorated with ligands that target receptors that are 585 overexpressed in cancer cells, such as the transferrin receptor 194 . Protein and antibody 586 tagging can also facilitate organ and cellular targeting; HER2 antibodies have been 587 conjugated to liposomal doxorubicin 165 to mediate targeted binding in breast cancer. 588 Antibody presentation on nanoparticles can also increase cellular particle uptake; when 589 trastuzumab and rituximab were bound to PLA particles, particle uptake was increased 590 six-fold compared with PLA particles lacking targeting molecules 195 . In an alternative 591 strategy, Abraxane, an albumin bound nanoparticle formulation of paclitaxel, is thought 592 to undergo an albumin-receptor (gp60) mediated endothelial transcytosis [196] [197] [198] , enabling 593 the drug to pass through endothelial cell walls in tumor micro vessels to achieve enhanced intra-tumoral concentrations and anti-tumor activity. 595
In addition to targeting specific cells, nanocarriers that contain cargo must also 596 efficiently enter cells to deliver the therapeutic component. Particle shape, size, and 597 composition can all affect penetration efficacy, and coating the nanoparticle with cell 598 penetrating peptides is proving a promising strategy. By screening a library of cell 599 penetrating peptides (CPP) using a high throughput strategy, three human peptides were 600 identified which improved in vivo delivery when conjugated to lipid-like 601 nanoparticles 199 . As the mechanism for cellular entry and endosomal escape become 602 better understood, new ligands will be identified to enhance these processes and 603 enhance intracellular targeting with increased specificity and efficiency. 604
Summary 605
Nano based systems are an enabling technology for the delivery of traditional drugs and 606 novel therapies such as nucleic acid based drugs. Nanoparticles can be used to optimize 607 the pharmacokinetics of conventional therapeutics, and offer a promising platform for 608 targeting specific cells and organelles by manipulating biological pathways such as 609 endocytosis and ligand targeting to gain cellular entry. Due to their small scale, drug 610 loading and precision engineering is challenging, rendering current nanoscale systems 611 less suited for the continued or controlled release of therapeutic loads. Additionally, the 612 development of safe and effective nanoscale materials presents a significant hurdle for 613 clinical translation. 614
CONCLUSIONS 615
Modern drug therapies include small molecules, proteins, and genetic 616 engineering based strategies. These therapies often have precise biological therapeutic 617 targets, and are most effective when delivered with specific dosing regimens. The need to combine targeted delivery and dosing in smaller and smaller scale systems has driven 619 the miniaturisation of drug delivery devices from the macro to micro to the nano scale. 620
We have reviewed a range of devices and described their ability to controllably deliver 621 biomolecules, summarised in Table 1 and Figure 4 . In general, macro devices offer 622 precisely engineered systems which can provide systemic and localised drug delivery 623 over a period of several years. Devices have a defined lifetime, usually limited by 624 battery power and reservoir capacity, before they need to be surgically replaced. In 625 some cases, precision engineering and the incorporation of wireless sensors for on-626 demand sensing has enabled patient specific drug delivery, most commonly applied to 627 insulin therapies. As the length scale of these devices is reduced to smaller macro 628 devices, they can be surgically implanted into additional target organs to enable 629 localised therapeutic delivery, however their scale limits their ability to target smaller 630 biological structures. In a smart workaround, cell specific delivery can be achieved 631 using macro scale polymer implants that recruit desired cells for targeted delivery, and 632 when coupled with refillable drug depots this will provide an exciting future direction 633 for cell specific delivery. 634
In contrast, micro and nano systems can often be coupled with targeting ligands and can 635 travel through the vasculature and lymphatic systems to reach specific cell targets. 636
Several of these systems can undergo burst release in response to external stimuli such 637 as light, heat, or ultrasound. However, there are limited examples of these systems being 638 able to intrinsically facilitate controlled dosing schedules. Notable exceptions are burst 639 release polymer particles which offer a single administration of an entire dosing 640 schedule, and stimuli responsive nanoneedle delivery systems which use cleavable 641 linkers to deliver therapeutics in response to target enzyme expression. These systems 642 straddle the boundary between sensing and drug delivery and offer an exciting direction 643 for responsive drug delivery therapies. A major limitation to micro and nano scale 644 systems is the limited therapeutic load these systems can carry, limiting the duration of 645 controlled release to between hours and, at most, a few months. This suggests micro-646 and nano-scale systems are best suited to short term delivery of up to 3 months, or the 647 targeted delivery of curative and preventative therapeutics that can be administered with 648 a single application. 649
Moving forwards, next generation devices will focus on increasing the efficacy of 650 therapeutic delivery at smaller and smaller length scales. As mechanisms of 651 nanoparticle cellular entry and endosomal escape are elucidated, nanoscale systems with 652 greater delivery efficacy and therapeutic effect will be developed. Additionally, the 653 development of stimuli responsive polymer systems will enable on-demand and patient-654 specific delivery systems to be developed in response to specific cues. Future devices 655 will combine the advantages of macro scale delivery systems with the precise targeting 656 capabilities of devices on the nano scale. 657 
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